Opioid crisis cost US government nearly $38 billion in lost taxes
April 11, 2019Medical Communications, Research and Development US, government, opioid crisis, opioids, public health, tax revenue
The opioid epidemic may have cost US state and federal governments as much as $37.8 billion in lost tax revenue, …
Traffic pollution linked to four million childhood asthma cases each year
April 11, 2019Research and Development Air pollution, NO2, Traffic, asthma, emissions, pollution, public health
Air pollution is linked to four million cases of childhood asthma each year, according to research published in The Lancet …
Living with a rare chromosome disorder
April 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Inv Dup Del 8p, feature, patient experience, pharma
Rebecca Pender’s daughter Hannah lives with the ultra-rare condition Inv Dup Del 8p, a genetic arrangement that affects just 80 …
Reckitt Benckiser to unveil £105 R&D site in Hull by end of June
April 11, 2019Manufacturing and Production Hull, R&D, Reckitt Benckiser, UK, pharma
Reckitt Benckiser (RB) has announced that its £105 million research and development facility in the UK city of Hull – …
Researchers use CRISPR to reveal gene targets in 30 types of cancer
April 11, 2019Research and Development Cancer, crispr, drug development, genes, genetics, oncology
Researchers at the Wellcome Sanger Institute and Open Targets have been able to identify thousands of genes which play a …
Novartis’ Kisqali combo rejected by NICE for advanced breast cancer
April 11, 2019Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma
Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, …
Gilead to lay off one fifth of sales force
April 11, 2019Sales and Marketing Gilead, Jobs, Letairis, Ranexa, redundancy, sales
Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents …
FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients
April 10, 2019Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …
Indivior shares fall by 70% after allegations of fraud
April 10, 2019Research and Development Virginia, indivior, opioid crisis, opioids, suboxone
Shares in London-listed Indivior plummeted this morning after US Federal prosecutors said the British drugmaker had deceived doctors as to …
Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer
April 10, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma
Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …
New Yorkers must be vaccinated or face a fine
April 10, 2019Research and Development Brooklyn, New York, infectious diseases, measles, public health, vaccines
A public health emergency has been declared in New York following an outbreak of measles. Residents of certain postcodes in …
Pharmacy Benefit Manager (PBM) execs testify before US Senate
April 10, 2019Research and Development PBMs, Rebates, Senate, US, pharma, senator, sfc
Executives representing pharmacy benefit managers (PBMs) appeared before the US Senate Finance Committee on Tuesday as they testified on the …
Epilepsy Society calls for review of UK supply chain following “steep rise” in access issues
April 9, 2019Manufacturing and Production, Sales and Marketing Epilepsy Society, UK, brexit, epilepsy, market access, pharma
The Epilepsy Society has drawn attention to the “steep rise” in UK patients who are encountering difficulty in accessing seizure …
United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure
April 9, 2019Manufacturing and Production, Research and Development Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertension
United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its …
FDA refuses to review Zogenix’s Fintepla in Dravet syndrome, shares tumble 30%
April 9, 2019Manufacturing and Production, Sales and Marketing Dravet Syndrome, FDA, Fintepla, Zogenix
California-based biopharma firm Zogenix has been left frustrated after it received a correspondence from the FDA noting its refusal to …
ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1
April 9, 2019Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma
ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …
Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer
April 8, 2019Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma
Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …
Kymab announces Merck exec Simon Sturge as new CEO
April 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, appointment, kymab, pharma
UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins …
Protecting public health: Is real-world evidence the key?
April 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, real world data, real world evidence, real-world data, real-world evidence
In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need …
NICE turns down Astellas’ Xtandi in prostate cancer
April 8, 2019Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer
Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
